Hemostemix Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	1.51	1.65	1.64	1.8	2.47	2.23
Research & Development	2.76	2.49	0	0.38	0.62	0.18
Operating Expenses	4.88	5.27	1.97	2.33	3.27	2.77
Operating Income	-4.88	-5.27	-1.97	-2.33	-3.27	-2.77
Interest Expense	-0.35	-0.45	-0.62	-0.55	-0.35	-0.09
Interest & Investment Income	-	-	-	-	-	0.07
Currency Exchange Gain (Loss)	0.03	-0.03	-0.01	0.02	0.18	0.14
Other Non Operating Income (Expenses)	-0.67	-0.47	-0.02	-0.01	-	-
EBT Excluding Unusual Items	-5.87	-6.22	-2.62	-2.87	-3.45	-2.65
Gain (Loss) on Sale of Investments	0.02	-0.11	-	-	-	-
Legal Settlements	-	-	-	0.18	-1.3	-3.89
Other Unusual Items	1.63	1.62	-	0.19	0	-
Pretax Income	-4.22	-4.71	-2.62	-2.5	-4.75	-6.54
Income Tax Expense	-	-	-	-	0.49	-0.26
Earnings From Continuing Operations	-4.22	-4.71	-2.62	-2.5	-5.24	-6.29
Net Income	-4.22	-4.71	-2.62	-2.5	-5.24	-6.29
Net Income to Common	-4.22	-4.71	-2.62	-2.5	-5.24	-6.29
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	181	163	95	82	70	57
Shares Outstanding (Diluted)	181	163	95	82	70	57
Shares Change	86.03%	71.93%	15.22%	17.89%	21.81%	78.19%
EPS (Basic)	-0.02	-0.03	-0.03	-0.03	-0.07	-0.11
EPS (Diluted)	-0.02	-0.03	-0.03	-0.03	-0.07	-0.11
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-5.69	-4.53	-1.9	-1.42	-6.1	-3.48
Free Cash Flow Per Share	-0.03	-0.03	-0.02	-0.02	-0.09	-0.06
EBITDA	-4.88	-5.27	-1.97	-2.33	-3.27	-2.77
D&A For EBITDA	0	0	0	0	0	0
EBIT	-4.88	-5.27	-1.97	-2.33	-3.27	-2.77